Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 11, 2022

SELL
$3.01 - $5.22 $270 - $469
-90 Reduced 32.14%
190 $1,000
Q3 2021

Oct 04, 2021

SELL
$19.74 - $28.7 $3,158 - $4,592
-160 Reduced 36.36%
280 $6,000
Q1 2021

Apr 15, 2021

BUY
$18.99 - $33.2 $1,709 - $2,988
90 Added 25.71%
440 $14,000
Q4 2020

Jan 25, 2021

SELL
$19.41 - $26.0 $1,941 - $2,600
-100 Reduced 22.22%
350 $8,000
Q3 2020

Oct 09, 2020

SELL
$24.69 - $31.6 $493 - $632
-20 Reduced 4.26%
450 $11,000
Q4 2019

Feb 12, 2020

BUY
$7.95 - $12.27 $2,067 - $3,190
260 Added 123.81%
470 $5,000
Q4 2017

Jan 30, 2018

SELL
$16.19 - $20.3 $1,619 - $2,030
-100 Reduced 32.26%
210 $4,000
Q3 2017

Oct 02, 2017

BUY
$15.52 - $18.94 $1,396 - $1,704
90 Added 40.91%
310 $0
Q2 2017

Aug 22, 2017

BUY
N/A
220
220 $0

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $202M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Hall Laurie J Trustee Portfolio

Follow Hall Laurie J Trustee and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hall Laurie J Trustee, based on Form 13F filings with the SEC.

News

Stay updated on Hall Laurie J Trustee with notifications on news.